-
41.发明授权MIKRORESERVOIRSYSTEM AUF BASIS VON POLYSILOXANEN UND AMBIPHILEN LÖSEMITTELN 有权MICRO水库系统中基于聚硅氧烷和两亲性SOLVENTS
公开(公告)号：EP1191927B1
公开(公告)日：2003-03-12
申请号：EP00936897.8
申请日：2000-06-20
发明人： MÜLLER, Walter
IPC分类号： A61K9/70
CPC分类号： A61K9/7069 , A61K9/7084 , A61K9/7092
摘要： The invention relates to a transdermal therapeutic system on the basis of polysiloxane which contains microreservoirs filled with an active substance and one ambiphilic solvent.
-
42.发明授权
公开(公告)号：EP1089719B1
公开(公告)日：2002-04-10
申请号：EP99927904.5
申请日：1999-06-08
CPC分类号： A61K9/7061 , A61K31/565 , Y10S977/939 , A61K2300/00
摘要： The invention relates to a transdermal therapeutic system in the form of a patch for controlled release of estradiol in combination with noresthisteron acetate, comprising a backing layer, a reservoir attached thereto and oversaturated with active substances, which is produced using polyacrylate contact-sensitive adhesives and crystallization inhibitors, in addition to a removable protective layer. The inventive system is characterized in that the crystallization inhibitor is a polymer containing an amino group.
-
43.发明公开
公开(公告)号：EP1067916A2
公开(公告)日：2001-01-17
申请号：EP99917831.2
申请日：1999-03-20
发明人： MÜLLER, Walter
IPC分类号： A61K9/70
CPC分类号： A61K9/7061 , A61K9/7069 , A61K31/381
摘要： The invention relates to a method for producing transdermal systems with free active agent bases. The invention is characterized in that, during the production of the system, the free active agent bases are released from active agent salts by reaction with a basic alkali metal salt.
-
44.发明公开D2-AGONIST ENTHALTENDES TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES PARKINSON-SYNDROMS UND VERFAHREN ZU SEINER HERSTELLUNG 有权D 2激动剂CONTAINING透皮治疗系统用于帕金森氏综合征和方法的用于制造治疗
公开(公告)号：EP1033978A1
公开(公告)日：2000-09-13
申请号：EP99910359.1
申请日：1999-03-18
发明人： MÜLLER, Walter , PECK, James, V.
IPC分类号： A61K9/70
CPC分类号： A61K9/7061 , A61K9/7023 , A61K9/703 , A61K9/7038 , A61K9/7069 , A61K9/7084 , A61K9/7092 , A61K31/381
摘要： The invention relates to a transdermal therapeutic system comprising a back layer which is inert with respect to the constituents of the matrix, a self-adhesive matrix layer containing an effective quantity of (-)-5,6,7,8,-tetrahydro-6-[propyl[2-(2-thienyl)-ethyl]amino]-1-naphthol, and a protective film which is to be removed before use. The invention is characterized by a matrix based on a non-aqueous polymer adhesive system, said system being based on acrylate or silicon, with a solubility for (-)-5,6,7,8,-tetrahydro-6-[propyl[2-(2-thienyl)-ethyl]amino]-1-naphthol of ≥5 % g/g. Said matrix is essentially free of inorganic silicate particles.
-
45.发明公开
公开(公告)号：EP2797588A1
公开(公告)日：2014-11-05
申请号：EP12810316.5
申请日：2012-12-28
发明人： DZEKAN, Horst , HOFFMANN, Hans-Rainer , HORSTMANN, Michael , MÜLLER, Walter , WIEDERSBERG, Sandra
IPC分类号： A61K9/70
CPC分类号： A61K9/7053 , A61K9/7069 , A61K31/325 , A61K31/381 , A61K31/439 , A61K31/485 , A61K31/496 , A61K31/5375
摘要： The invention relates to transdermal therapeutic systems for dispensing a pharmaceutical product, in particular a pharmaceutical product with a low tendency to spontaneously crystallize. The matrix layer or at least one of the matrix layers in said systems contains a silicone hot-melt adhesive, a pharmaceutical product, and particles made of crosslinked polyvinylpyrrolidone. The invention also relates to a method for producing said transdermal therapeutic systems.
-
公开(公告)号：EP2760436A1
公开(公告)日：2014-08-06
申请号：EP12762597.8
申请日：2012-09-25
发明人： MÜLLER, Walter , MOHR, Patrick
摘要： The invention relates to a transdermal or topical plasters that contain active ingredient, comprising a non-occlusive back layer, a matrix composed of one or more polymer layers having at least one pharmaceutical active ingredient in one or more of the layers, wherein the structure-forming base polymers of the layer(s) are non-occlusive or only slightly occlusive and a second polymer that has a low water-vapor permeability and that is immiscible or only very slightly miscible with the base polymer is dispersed in at least one of the polymer layers.
摘要翻译： 提供了含有活性成分的透皮或局部膏药，其包括非闭合性背层，由一层或多层聚合物层形成的基质，所述聚合物层在一层或多层中具有至少一种药物活性成分，其中结构形成基质 层的聚合物是非闭塞的或仅仅是轻微闭塞的，并且具有低水蒸汽渗透性并且与基础聚合物不混溶或仅仅非常轻微混溶的第二聚合物分散在至少一个聚合物层 。
-
47.发明公开POLYVINYLPYRROLIDONE FOR THE STABILIZATION OF A SOLID DISPERSION OF THE NON-CRYSTALLINE FORM OF ROTIGOTINE 有权罗替高汀的非结晶形式的固体分散体聚乙烯吡咯烷酮镇定
公开(公告)号：EP2515887A1
公开(公告)日：2012-10-31
申请号：EP10796399.3
申请日：2010-12-22
IPC分类号： A61K9/70 , A61K31/381
CPC分类号： A61K9/7069 , A61K9/7053 , A61K31/381
摘要： The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
-
公开(公告)号：EP2094250B1
公开(公告)日：2010-04-28
申请号：EP07846633.1
申请日：2007-11-16
CPC分类号： A61K31/19 , A61K9/7069 , A61K9/7092 , A61K31/195 , A61K31/4164 , A61K31/437 , A61K31/4439 , A61K31/445 , A61K31/485 , A61K31/505 , A61K31/535 , A61K31/60
-
49.发明授权
公开(公告)号：EP1418951B1
公开(公告)日：2010-01-20
申请号：EP02754860.1
申请日：2002-07-10
发明人： MÜLLER, Walter
IPC分类号： A61K9/70
CPC分类号： A61K9/7069 , A61K9/7092
-
50.发明授权TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON'S DISEASE INDUCING HIGH PLASMA LEVELS OF ROTIGOTINE 无效帕金森病的透皮治疗系统具有高罗替高汀血浆MIRROR
公开(公告)号：EP1471892B1
公开(公告)日：2009-09-30
申请号：EP02740569.5
申请日：2002-05-06
IPC分类号： A61K9/70 , A61K31/381
CPC分类号： A61K9/7061 , A61K9/7069 , A61K31/381
摘要： This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm2 and containing 0.1 to 3.15 mg/cm2 of rotigotine as active ingredient, for the preparation of an anti-Parkinson medicament which induces a mean plasma concentration of rotigotine in the range of 0.4 to 2 ng/ml 24 h after administration.
-
-
-
-
-
-
-
-
-
搜索结果
60 条记录 (耗时 0.019 秒)
